The Biostatistics Core provides statistical expertise and data management support for each of the SPORE projects, the Developmental Research Program projects, and the Cores. Functions of the Biostatistics Core include the development of statistical designs and analysis plans, data acquisition and database development, data form development and processing, monitoring data flow, timeliness, and consistency, monitoring patient safety in studies involving human subjects, data analysis and interpretation, manuscript and presentation preparation, and data archiving. The primary objectives of the Biostatistics Core are: 1. To collaborate with each of the SPORE project teams and the Developmental Research Program project teams on the deyelppment of laboratory, animal, and human studies providing statistical design options and feasibility assessments. 2. To provide a statistical analysis plan for each project and to develop and evaluate alternative statistical data analysis methods. 3. To carry out the statistical analysis plan. 4. To collaborate in the interpretation of study results and preparation of presentations and manuscripts. 5. To provide relational database design, data form development and tracking, monitoring of data consistency, and archiving of data. 6. To provide an opportunity for all members of the Core to discuss and work through statistical and data management issues together. The existence of the Biostatistics Core assures each investigator access to statistical expertise which includes state of the art data analysis and data management resources as well as provides a mechanism of consistent and compatible data handling. This Core builds upon the innovative and time-tested procedures and systems developed by one of the largest statistical groups in the country, the Mayo Clinic Division of Biostatistics, as well as the NCI-funded Mayo Clinic Cancer Center Statistical Unit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-05
Application #
7890429
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$271,199
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Tu, Xinyi; Kahila, Mohamed M; Zhou, Qin et al. (2018) ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Mol Cancer Ther 17:2462-2472
Athreya, Arjun P; Gaglio, Alan J; Cairns, Junmei et al. (2018) Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer. IEEE Trans Nanobioscience 17:251-259
Wiese, Elizabeth K; Hitosugi, Taro (2018) Tyrosine Kinase Signaling in Cancer Metabolism: PKM2 Paradox in the Warburg Effect. Front Cell Dev Biol 6:79
Frank, Ryan D; Winham, Stacey J; Vierkant, Robert A et al. (2018) Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer 124:3319-3328
Degnim, Amy C; Winham, Stacey J; Frank, Ryan D et al. (2018) Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. J Clin Oncol 36:1840-1846
Ohmine, Seiga; Salisbury, Jeffrey L; Ingle, James et al. (2018) Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells. Oncol Rep 39:1725-1730
Kourtidis, Antonis; Anastasiadis, Panos Z (2018) Close encounters of the RNAi kind: the silencing life of the adherens junctions. Curr Opin Cell Biol 54:30-36
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Ho, Ming-Fen; Lummertz da Rocha, Edroaldo; Zhang, Cheng et al. (2018) TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor ?B p65: Single Nucleotide Polymorphism and Estrogen Dependence. J Pharmacol Exp Ther 365:700-710
Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574

Showing the most recent 10 out of 473 publications